Difference between revisions of "Erlotinib (Tarceva)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| + | Also known as Erlotinib hydrochloride. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Small molecule tyrosine kinase inhibitor. Inhibits the intracellular phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase; may also have activity against other tyrosine kinase receptors. Exact mechanism of antitumor action is not fully characterized.<ref name="insert">[http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf Erlotinib (Tarceva) package insert]</ref><ref>[ | + | Class/mechanism: Small molecule tyrosine kinase inhibitor. Inhibits the intracellular phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase; may also have activity against other tyrosine kinase receptors. Exact mechanism of antitumor action is not fully characterized.<ref name="insert">[http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf Erlotinib (Tarceva) package insert]</ref><ref>[[Media:Erlotinib.pdf | Erlotinib (Tarceva) package insert (locally hosted backup)]]</ref><ref>[http://tarceva.com Tarceva manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Unknown primary | Cancer of unknown primary]] | ||
| + | *[[Esophageal cancer]] | ||
| + | *[[Hepatobiliary cancer]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Pancreatic cancer]] | ||
| + | *[[Renal cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/erlotinib.aspx Erlotinib (Tarceva) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/erlotinib.aspx Erlotinib (Tarceva) patient drug information (Chemocare)]</ref> |
| + | *Brief patient counseling information can be found on [http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf#page=24 page 24 of the Erlotinib (Tarceva) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/erlotinib-patient-drug-information Erlotinib (Tarceva) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/erlotinib-patient-drug-information Erlotinib (Tarceva) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/erlotinib-patient-drug-information Erlotinib (Tarceva) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/erlotinib-patient-drug-information Erlotinib (Tarceva) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Tyrosine kinase inhibitors]] | ||
| + | [[Category:EGFR inhibitors]] | ||
| + | [[Category:Cancer of unknown primary medications]] | ||
| + | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Pancreatic cancer medications]] | ||
| + | [[Category:Renal cancer medications]] | ||
Revision as of 06:55, 16 October 2012
Also known as Erlotinib hydrochloride.
General information
Class/mechanism: Small molecule tyrosine kinase inhibitor. Inhibits the intracellular phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase; may also have activity against other tyrosine kinase receptors. Exact mechanism of antitumor action is not fully characterized.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Cancer of unknown primary
- Esophageal cancer
- Hepatobiliary cancer
- Non-small cell lung cancer
- Pancreatic cancer
- Renal cancer
Patient drug information
- Erlotinib (Tarceva) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 24 of the Erlotinib (Tarceva) package insert[1]
- Erlotinib (Tarceva) patient drug information (UpToDate)[5]